Search research articles
Contact Us
Filters
Showing results (31-40 of 57) with videos related to
Page
of 6
Sort By:
Frontiers in Immunology
|
September 9, 2020
Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors
Richard J Jones, Ram K Singh, Fazal Shirazi, et al.
Frontiers in Immunology
|
March 9, 2026
Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience
Naimisha Marneni, Spencer Lessans, Bhagirathbhai Dholaria, et al.
Bone Marrow Transplantation
|
March 25, 2025
Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial
Bhagirathbhai Dholaria, Shakthi T Bhaskar, Vivek G Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 4, 2026
Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey
Nadine H Abdallah, Jay R Hydren, Mason S Barnes, et al.
Current Medical Research and Opinion
|
February 18, 2026
Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers
Benjamin Derman, Jane Jijun Liu, Nicholas Bouchard, et al.
Circulation Research
|
June 23, 2009
Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis
Andrea T Hooper, Sergey V Shmelkov, Sunny Gupta, et al.
Nature Medicine
|
April 27, 2010
Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice
Sergey V Shmelkov, Adília Hormigo, Deqiang Jing, et al.
Annals of Hematology
|
March 25, 2017
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
Muhamed Baljevic, Shadia Zaman, Veerabhadran Baladandayuthapani, et al.
JCO Oncology Practice
|
December 4, 2025
Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide
Kian J Rahbari, Raul Del Toro Mijares, Kathryn Kennedy, et al.
Bone Marrow Transplantation
|
December 27, 2025
Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience
Ihunayachi Ohuabunwa, Bhagirathbhai Dholaria, Megan Wanca, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 57) with videos related to
Sort By:
Page
of 6
Frontiers in Immunology
|
September 9, 2020
Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors
Richard J Jones, Ram K Singh, Fazal Shirazi, et al.
Frontiers in Immunology
|
March 9, 2026
Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience
Naimisha Marneni, Spencer Lessans, Bhagirathbhai Dholaria, et al.
Bone Marrow Transplantation
|
March 25, 2025
Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial
Bhagirathbhai Dholaria, Shakthi T Bhaskar, Vivek G Patel, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 4, 2026
Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey
Nadine H Abdallah, Jay R Hydren, Mason S Barnes, et al.
Current Medical Research and Opinion
|
February 18, 2026
Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers
Benjamin Derman, Jane Jijun Liu, Nicholas Bouchard, et al.
Circulation Research
|
June 23, 2009
Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis
Andrea T Hooper, Sergey V Shmelkov, Sunny Gupta, et al.
Nature Medicine
|
April 27, 2010
Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice
Sergey V Shmelkov, Adília Hormigo, Deqiang Jing, et al.
Annals of Hematology
|
March 25, 2017
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
Muhamed Baljevic, Shadia Zaman, Veerabhadran Baladandayuthapani, et al.
JCO Oncology Practice
|
December 4, 2025
Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide
Kian J Rahbari, Raul Del Toro Mijares, Kathryn Kennedy, et al.
Bone Marrow Transplantation
|
December 27, 2025
Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience
Ihunayachi Ohuabunwa, Bhagirathbhai Dholaria, Megan Wanca, et al.
Page
of 6